Emily S. Chambers

Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action

James M. McFarland, Brenton R. Paolella, Allison Warren et al. · Nature Communications · 2020 · 175 citations · Full text

Anti–PD-1 Inhibitor–Related Pneumonitis in Non–Small Cell Lung Cancer

Mizuki Nishino, Emily S. Chambers, Curtis R. Chong et al. · Cancer Immunology Research · 2016 · 148 citations · Full text

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma

Natalie I. Vokes, Emily S. Chambers, Tom Nguyen et al. · Journal of Thoracic Oncology · 2022 · 142 citations · Full text

Tumor Heterogeneity, Medicine, Egfr-mutant Lung Adenocarcinoma +11

Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients

Mizuki Nishino, Nikhil H. Ramaiya, Emily S. Chambers et al. · Journal for ImmunoTherapy of Cancer · 2016 · 112 citations · Full text

Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non–Small Cell Lung Cancer

Magda Bahcall, Mark M. Awad, Lynette M. Sholl et al. · Clinical Cancer Research · 2018 · 82 citations · Full text